QQ客服 官方微博 反馈留言

	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
	Hou, Jian; Jin, Jie; Xu, Yan; Wu, Depei; Ke, Xiaoyan; Zhou, Daobin; Lu, Jin; Du, Xin; Chen, Xiequn; Li, Junmin
	2017
卷号	10期号:1页码:137
关键词	China Ixazomib Multiple myeloma Oral Overall survival Progression-free survival Proteasome inhibitor Relapsed/refractory
ISSN号	1756-8722
DOI	10.1186/s13045-017-0501-4
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6365410
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hou, Jian,Jin, Jie,Xu, Yan,et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study[J],2017,10(1):137.
APA	Hou, Jian.,Jin, Jie.,Xu, Yan.,Wu, Depei.,Ke, Xiaoyan.,...&Moreau, Philippe.(2017).Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.,10(1),137.
MLA	Hou, Jian,et al."Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study".10.1(2017):137.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。